Subthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40
Table 1
Sample demographics.
Variable
Treatment group
value
Group I: eyes with BCVA 20/40
Group II: eyes with BCVA 20/40
Eyes,
15
17
Sex, (%)
Male
12 (80.0)
11 (64.7)
0.337
Female
3 (20.0)
6 (35.3)
Age, mean (SD), years
70.53 (10.78)
63.65 (7.66)
0.044
Hypertension, (%)
9 (60.0)
10 (58.8)
0.946
Cardiovascular disease, (%)
5 (33.3)
1 (5.9)
0.047
Diabetes, (%)
3 (20.0)
4 (23.5)
0.810
BRVO type
Ischemic
7
6
0.513
Nonischemic
8
11
Macular BRVO
7
7
0.755
Additional MP treatment, (%)
8 (53.3)
3 (17.6)
0.034
Baseline BCVA (SD), log MAR
0.5933 (0.2277)
0.1263 (0.0769)
0.355
Baseline CMT (SD), µm
409.266 (87.955)
373.294 (100.268)
0.756
Baseline TMV (SD), mm3
8.1273 (0.8761)
8.175 (2.8895)
0.952
BCVA: best-corrected visual acuity; BRVO: branch retinal vein occlusion; MP: micropulse photocoagulation; CMT: central macular thickness; TMV: total macular volume.
